TABLE 2.
Baseline characteristics of the high‐dimensional propensity score‐matched cohorts
| Without history of diabetes | Without history of MI, stroke or cancer | |||||
|---|---|---|---|---|---|---|
| Chlorprothixene | Quetiapine | Chlorprothixene | Quetiapine | |||
| (N = 43 094) | (N = 43 094) | SMD | (N = 42 818) | (N = 42 818) | SMD | |
| Sex, N (%) | ||||||
| Female | 23 079 (54) | 22 657 (53) | <0.1 | 22 916 (54) | 22 768 (53) | <0.1 |
| Age, N (%) | ||||||
| Median (IQR) | 41 (27–55) | 39 (26–53) | 40 (26–53) | 39 (26–51) | ||
| 0–17 years | 2673 (6) | 2104 (5) | 0.1 | 3308 (8) | 2148 (5) | 0.1 |
| 18–44 years | 21 739 (50) | 23 816 (55) | 0.1 | 21 984 (51) | 24 406 (57) | 0.1 |
| 45–64 years | 13 177 (31) | 11 316 (26) | 0.1 | 12 717 (30) | 11 995 (28) | <0.1 |
| 65–85 years | 5505 (13) | 5858 (14) | <0.1 | 4809 (11) | 4269 (10) | <0.1 |
| Year of cohort entry, N (%) | ||||||
| 2000–2005 | 1432 (3) | 1727 (4) | <0.1 | 1139 (3) | 1465 (3) | <0.1 |
| 2006–2011 | 18 779 (44) | 18 621 (43) | <0.1 | 18 864 (44) | 18 843 (44) | <0.1 |
| 2012–2017 | 22 883 (53) | 22 746 (53) | <0.1 | 22 815 (53) | 22 510 (53) | <0.1 |
| Comorbidities, N (%) | ||||||
| Ischaemic heart disease | 2096 (5) | 2006 (5) | <0.1 | 1525 (4) | 1319 (3) | <0.1 |
| Heart failure | 510 (1) | 542 (1) | <0.1 | 380 (<1) | 350 (<1) | <0.1 |
| Peripheral vascular disease | 845 (2) | 844 (2) | <0.1 | 737 (2) | 625 (1) | <0.1 |
| Hypertension | 6546 (15) | 6101 (14) | <0.1 | 6514 (15) | 5808 (14) | <0.1 |
| COPD | 5886 (14) | 5196 (12) | <0.1 | 5725 (13) | 5070 (12) | <0.1 |
| Diabetes | ‐ | ‐ | ‐ | 2083 (5) | 2006 (5) | <0.1 |
| Obesity | 2544 (6) | 2521 (6) | <0.1 | 2955 (7) | 3072 (7) | <0.1 |
| Alcohol‐related disorders | 12 690 (29) | 13 100 (30) | <0.1 | 12 737 (30) | 13 210 (31) | <0.1 |
| Neurological disorders | 6766 (16) | 7211 (17) | <0.1 | 6460 (15) | 6885 (16) | <0.1 |
| Dementia | 564 (1) | 2046 (5) | 0.2 | 540 (1) | 1149 (3) | 0.1 |
| Major depression | 10 199 (24) | 12 764 (30) | 0.1 | 9518 (22) | 13 963 (33) | 0.2 |
| Anxiety disorders | 14 669 (34) | 15 185 (35) | <0.1 | 14 798 (35) | 15 388 (36) | <0.1 |
| Personality disorders | 5134 (12) | 5915 (14) | 0.1 | 5093 (12) | 6095 (14) | 0.1 |
| Drugs used in the past year, N (%) | ||||||
| Acetylsalicylic acid | ‐ | ‐ | ‐ | 2444 (6) | 2193 (5) | <0.1 |
| Statins | ‐ | ‐ | ‐ | 4016 (9) | 3547 (8) | <0.1 |
| Antidiabetic agents | ‐ | ‐ | ‐ | 1744 (4) | 1702 (4) | <0.1 |
| Oral glucocorticoids | 2500 (6) | 2370 (5) | <0.1 | ‐ | ‐ | ‐ |
| Mirtazapine | 7499 (17) | 6803 (16) | <0.1 | ‐ | ‐ | ‐ |
| Antihistamines | 4058 (9) | 3711 (9) | <0.1 | ‐ | ‐ | ‐ |
| Haemoglobin A1c at baseline, N (%) a | ||||||
| Normal | 2377 (6) | 2436 (6) | <0.1 | ‐ | ‐ | ‐ |
| Prediabetes | 751 (2) | 609 (1) | <0.1 | ‐ | ‐ | ‐ |
| Missing | 39 966 (93) | 40 049 (93) | <0.1 | ‐ | ‐ | ‐ |
Abbreviations: COPD, chronic obstructive pulmonary disease; IQR, interquartile range; MI, myocardial infarction; N, number; SMD, standardized mean difference.
a
Prediabetes at baseline defined as haemoglobin A1c 39–47 mmol/mol or 5.7–6.3%.